% | $
Quotes you view appear here for quick access.

Amgen Inc. Message Board

  • ra9909 ra9909 Dec 9, 2011 2:09 PM Flag

    Here is what powerful Goldman said today

    Amgen's Epogen headwinds increasing, says Goldman:

    Goldman said the favorable FDA panel recommendation for Affymax's (AFFY) Peginesatide increases headwinds for Amgen's (AMGN) Epogen and views it as another step towards lower Epogen sales and pricing. Shares are Sell rated with a $50 price target.

158.30-2.26(-1.41%)Apr 29 4:00 PMEDT